Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

103.36 +0.79 (+0.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
22 23 Next >
What 10 Analyst Ratings Have To Say About Axsome Therapeutics
Via Benzinga
Can Axsome Hold Out Till Depression Drug Becomes a Blockbuster?
Has the company bitten off more than it can chew in R&D, or will its depression drug launch it into the stratosphere? 
Via The Motley Fool
A New Nasdaq Bull Market Is Nearly Here: 3 Stocks to Buy Sooner Rather Than Later
These stocks share one big thing in common -- huge growth prospects. 
Via The Motley Fool
Has Axsome Therapeutics Become a No-Brainer Buy?
The stock has been red-hot over the past year, and analysts remain bullish on it. 
Via The Motley Fool
Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today
Macro headwinds are weighing on risk-laden biotech stocks today. 
Via The Motley Fool
2 Top Biotech Stocks to Buy in April
Right now you can pick up these stocks on the dip. 
Via The Motley Fool
Expert Ratings for Axsome Therapeutics
Via Benzinga
Is Axsome Therapeutics Stock a Buy Now?
The biotech made major progress on the regulatory front last year. 
Via The Motley Fool
Axsome Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Analyst Expectations for Axsome Therapeutics's Future
Via Benzinga
3 Surprisingly Underrated Stocks to Buy in April
These drugmakers could deliver greater gains than many investors expect. 
Via The Motley Fool
The Top Healthcare Stocks to Buy With $100
With the right stocks, even a small investment can yield huge returns. 
Via The Motley Fool
The 3 Best Growth Stocks to Buy in the Biotech Sector
These three biotech growth stocks are brimming with potential and could offer massive upside for patient investors. 
Via InvestorPlace
3 Up-and-Coming Growth Stocks to Buy Right Now
These companies are small now but could grow much larger over time. 
Via The Motley Fool
2 Biotech Stocks That Could Make You Richer
One is a well-established, large-cap drugmaker, while the other is still making a name for itself in the industry. 
Via The Motley Fool
Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money
There are no guarantees that any stock will generate huge returns. But the odds look pretty good for these three growth stocks. 
Via The Motley Fool
Axsome Therapeutics's Earnings: A Preview
Via Benzinga
Biotech Stocks And The SVB Collapse — Here's What We Know
The collapse of SVB will have a big impact on early-stage, venture-backed companies. 
Via Investor's Business Daily
3 Nasdaq Stocks on Watch This Week
These three Nasdaq stocks are poised to make big moves in the coming week. 
Via The Motley Fool
5 Top Stocks for March
These five businesses are worth a look for patient investors. 
Via The Motley Fool
Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics (AXSM) Q4 2022 Earnings Call Transcript
AXSM earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Why Axsome Therapeutics (AXSM) Shares Are Trading Higher
Axsome Therapeutics Inc (NASDAQ: AXSM) shares are trading higher by 3.22% to $63.02 Monday morning after the company reported mixed fourth-quarter financial results. What Happened? 
Via Benzinga
Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
A New Bull Market Is in Sight: 3 Stocks to Buy Sooner Rather Than Later
All three of these stocks have impressive growth prospects. 
Via The Motley Fool
Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Long Term Investor Alert: Lawsuit Against Directors Filed
San Diego, CA -- (SBWIRE) -- 02/17/2023 -- An investor in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) filed a lawsuit against certain directors of Axsome Therapeutics, Inc. over alleged breaches... 
Via SBWire
Earnings Scheduled For February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. 
Via Benzinga
Meta Platforms Layoffs 2023: What to Know as Facebook Preps More Job Cuts
Meta Platforms (META) layoffs are a hot topic among traders Monday as the Facebook parent company reportedly considering more job cuts. 
Via InvestorPlace
Axsome Therapeutics (AXSM) Stock Falls as Teva Pursues Generic Depression Drug
Axsome Therapeutics (AXSM) stock is taking a beating on Monday as rival Teva Pharmaceutical (TEVA) prepares a generic depression drug. 
Via InvestorPlace
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.